Key result
Inhibitors of the renin-angiotensin system, such as ACE inhibitors and ARBs, may reduce the incidence of new-onset diabetes by improving insulin sensitivity and protecting pancreatic beta-cells.
Why the study?
Do renin-angiotensin system inhibitors reduce the incidence of new-onset diabetes in patients at high risk of developing diabetes?
Do renin-angiotensin system inhibitors reduce the incidence of new-onset diabetes in patients at high risk of developing diabetes?
RAS inhibitors may prevent new-onset diabetes via hemodynamic effects and direct protection of pancreatic beta-cells, warranting prospective clinical trials.
No takes yet. Share an insight, caveat, or question.
Supports potential diabetes prevention with RAS inhibitors; leaves open confirmation in prospective randomized trials.
Jandeleit‐Dahm et al. (2005) conducted a review in High risk of developing diabetes. Inhibitors of the renin-angiotensin system (ACE inhibitors and ARBs) was evaluated on Incidence of new-onset diabetes. Inhibitors of the renin-angiotensin system, such as ACE inhibitors and ARBs, may reduce the incidence of new-onset diabetes by improving insulin sensitivity and protecting pancreatic beta-cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: